Zogenix To Present New FINTEPLA® (fenfluramine) Data at AES

Data add to the growing body of evidence supporting the efficacy and safety profile of FINTEPLA for the treatment of Dravet syndrome...

Related Keywords

Japan ,United States ,Chicago ,Illinois ,American ,Porter Novelli ,Trish Mccall ,Tevard Biosciences ,Bradleys Galer ,Brian Ritchie ,Us Securities Exchange Commission ,Lifesci Advisors ,American Epilepsy Society ,European Commission ,Drug Administration ,European Early Access Program ,European Medicines Agency ,Annual Meeting ,Better Outcomes Through Diversity ,Executive Vice President ,Chief Medical Officer ,Zogenix Newsroom ,Treatment Improves Everyday Executive Functioning ,Preschool Children With Dravet Syndrome ,Analysis From ,Significantly Reduces Day To Seizure Burden ,Increasing Seizure Free Days ,Time To Event Analysis ,Echocardiographic Assessment ,Dravet Syndrome Treated ,Valvular Heart Disease ,Pulmonary Artery ,Provides Clinically Meaningful ,Durable Improvement ,Seizure Frequency ,Patients With Dravet Syndrome Regardless ,European Early Access ,Pathophysiologic Process Linked ,Exhibits Disease Modifying Effects ,Mouse Model ,Serotonin Receptor Agonist ,Disease Modification ,Scientific Exhibit Room ,Zogenix Scientific Exhibit ,Scientific Exhibition Room ,Patients With Lennox Gastaut Syndrome ,Gastaut Syndrome ,Heart Disease ,Pulmonary Arterial Hypertension ,Prescribing Information ,Boxed Warning ,New Drug Application ,Priority Review ,Private Securities Litigation Reform Act ,Nasdaq Zgnx ,Rogenix ,Nc ,